{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T17:00:39Z","timestamp":1794243639222,"version":"4.9.0"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["bmn.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Pharmacology"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.coph.2019.01.001","type":"journal-article","created":{"date-parts":[[2019,4,8]],"date-time":"2019-04-08T15:50:05Z","timestamp":1554738605000},"page":"44-49","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Pharmacological advances in pemphigus"],"prefix":"10.1016","volume":"46","author":[{"given":"Asli","family":"Bilgic Temel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dedee F","family":"Murrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coph.2019.01.001_bib0005","doi-asserted-by":"crossref","first-page":"607","DOI":"10.2340\/00015555-2611","article-title":"Mortality and cause of death in patients with pemphigus","volume":"97","author":"Kridin","year":"2017","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.coph.2019.01.001_sbref0010","doi-asserted-by":"crossref","first-page":"757","DOI":"10.2147\/TCRM.S142471","article-title":"Emerging treatment options for the management of pemphigus vulgaris","volume":"14","author":"Kridin","year":"2018","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.coph.2019.01.001_bib0015","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/jdv.12772","article-title":"Pemphigus. S2 guideline for diagnosis and therapy \u2013 guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV)","volume":"29","author":"Hertl","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.coph.2019.01.001_bib0020","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1182\/blood.V83.2.435.435","article-title":"Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20","volume":"83","author":"Reff","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.coph.2019.01.001_sbref0025","article-title":"Diagnosis and management of pemphigus: recommendations by an international panel of experts","author":"Murrell","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.coph.2019.01.001_sbref0030","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1016\/S0140-6736(17)30070-3","article-title":"First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial","volume":"389","author":"Joly","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.coph.2019.01.001_bib0035","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/j.1610-0387.2007.06602.x","article-title":"Recommendations for the use of rituximab (anti-CD20 antibody) in the treatment of autoimmune bullous skin diseases","volume":"6","author":"Hertl","year":"2008","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.coph.2019.01.001_bib0040","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1111\/jdv.12678","article-title":"An assessment of treatment history and its association with clinical outcomes and relapse in 155 pemphigus patients with response to a single cycle of rituximab","volume":"29","author":"Amber","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.coph.2019.01.001_sbref0045","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s13317-017-0100-y","article-title":"Next-generation anti-CD20 monoclonal antibodies in autoimmune disease treatment","volume":"8","author":"Du","year":"2017","journal-title":"Auto Immun Highlights"},{"key":"10.1016\/j.coph.2019.01.001_bib0050","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1001\/jamadermatol.2014.1939","article-title":"Subcutaneous veltuzumab, a humanized anti-CD20 antibody, for treatment of refractory pemphigus vulgaris","volume":"150","author":"Ellebrecht","year":"2014","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.coph.2019.01.001_bib0055","unstructured":"http:\/\/www.pemphigus.org\/veltuzumab-granted-orphan-drug-status\/."},{"key":"10.1016\/j.coph.2019.01.001_bib0060","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/bjh.12448","article-title":"Low-dose anti-CD20 veltuzumab given intravenously or subcutaneously is active in relapsed immune thrombocytopenia: a phase I study","volume":"162","author":"Liebman","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.coph.2019.01.001_bib0065","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1093\/rheumatology\/keh533","article-title":"Humanized anti-CD20 monoclonal antibody in the treatment of severe resistant systemic lupus erythematosus in a patient with antibodies against rituximab","volume":"44","author":"Tahir","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.coph.2019.01.001_bib0070","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01920477."},{"key":"10.1016\/j.coph.2019.01.001_bib0075","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.3389\/fimmu.2017.01454","article-title":"Bruton\u2019s tyrosine kinase: an emerging key player in innate immunity","volume":"8","author":"Weber","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.coph.2019.01.001_bib0080","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/ajd.12615","article-title":"Successful use of Bruton\u2019s kinase inhibitor, ibrutinib, to control paraneoplastic pemphigus in a patient with paraneoplastic autoimmune multiorgan syndrome and chronic lymphocytic leukaemia","volume":"58","author":"Lee","year":"2017","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.coph.2019.01.001_sbref0085","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1111\/bcp.13351","article-title":"A phase I trial of PRN1008, a novel reversible covalent inhibitor of Bruton\u2019s tyrosine kinase, in healthy volunteers","volume":"83","author":"Smith","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.coph.2019.01.001_bib0090","article-title":"A new treatment for autoimmune blistering diseases \u2013 the efficacy of the Bruton\u2019s tyrosine kinase inhibitor PRN473 in canine pemphigus foliaceus","volume":"74","author":"Outerbridge","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.coph.2019.01.001_bib0095","unstructured":"A Study of PRN1008 in Adult Patients with Pemphigus Vulgaris https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02704429 BTK Inhibitor | autoimmune diseases | Principia Biopharma https:\/\/www.principiabio.com\/pipeline\/btk-prn1008. An encouraging study showing promising preliminary results of a phase II open-label cohort study examining PRN1008 in adult patients with PV."},{"key":"10.1016\/j.coph.2019.01.001_sbref0100","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1126\/science.aaf6756","article-title":"Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease","volume":"353","author":"Ellebrecht","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.coph.2019.01.001_bib0105","doi-asserted-by":"crossref","first-page":"3781","DOI":"10.1172\/JCI64413","article-title":"Pemphigus autoantibodies generated through somatic mutations target the desmoglein-3 cis-interface","volume":"122","author":"Di Zenzo","year":"2012","journal-title":"J Clin Invest"},{"key":"10.1016\/j.coph.2019.01.001_bib0110","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1002\/art.1780401002","article-title":"CD40\u2013CD40 ligand interaction in autoimmune disease","volume":"40","author":"Datta","year":"1997","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.coph.2019.01.001_bib0115","doi-asserted-by":"crossref","first-page":"6550","DOI":"10.1073\/pnas.89.14.6550","article-title":"A 39-kDa protein on activated helper T cells binds CD40 and transduces the signal for cognate activation of B cells","volume":"89","author":"Noelle","year":"1992","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coph.2019.01.001_bib0120","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/jlb.63.4.418","article-title":"The role of CD40\/CD154 interactions in the priming, differentiation, and effector function of helper and cytotoxic T cells","volume":"63","author":"Mackey","year":"1998","journal-title":"J Leukocyte Biol"},{"key":"10.1016\/j.coph.2019.01.001_sbref0125","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/sj.jid.5700016","article-title":"Tolerance induction by the blockade of CD40\/CD154 interaction in pemphigus vulgaris mouse model","volume":"126","author":"Aoki-Ota","year":"2006","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.coph.2019.01.001_sbref0130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-3083.2010.02470.x","article-title":"Functional and clinical aspects of the B-cell- activating factor (BAFF): a narrative review","volume":"73","author":"Lied","year":"2011","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.coph.2019.01.001_bib0135","first-page":"465","article-title":"BAFF: a fundamental survival factor for B cells","volume":"2","author":"Mackay","year":"2002","journal-title":"Immunology"},{"key":"10.1016\/j.coph.2019.01.001_bib0140","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/j.1365-2133.2006.07305.x","article-title":"Serum levels of BAFF are increased in bullous pemphigoid but not in pemphigus vulgaris","volume":"155","author":"Asashima","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.coph.2019.01.001_bib0145","doi-asserted-by":"crossref","first-page":"3475","DOI":"10.1002\/art.11354","article-title":"B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations","volume":"48","author":"Stohl","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.coph.2019.01.001_bib0150","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1002\/art.21526","article-title":"Elevated serum BAFF levels in patients with systemic sclerosis: enhanced BAFF signaling in systemic sclerosis B lymphocytes","volume":"54","author":"Matsushita","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.coph.2019.01.001_bib0155","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.humimm.2007.03.010","article-title":"Elevated serum BAFF in patients with autoimmune hepatitis","volume":"68","author":"Migita","year":"2007","journal-title":"Hum Immunol"},{"key":"10.1016\/j.coph.2019.01.001_bib0160","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1600-0625.2006.00485.x","article-title":"Elevated serum BAFF levels in patients with localized scleroderma in contrast to other organ-specific autoimmune diseases","volume":"16","author":"Matsushita","year":"2007","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.coph.2019.01.001_bib0165","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1084\/jem.189.11.1747","article-title":"BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth","volume":"189","author":"Schneider","year":"1999","journal-title":"J Exp Med"},{"key":"10.1016\/j.coph.2019.01.001_bib0170","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1172\/JCI18025","article-title":"BAFF selectively enhances the survival of plasmablasts generated from human memory B cells","volume":"112","author":"Avery","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1016\/j.coph.2019.01.001_bib0175","unstructured":"https:\/\/ard.bmj.com\/content\/75\/Suppl_2\/300.3."},{"key":"10.1016\/j.coph.2019.01.001_bib0180","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03574545."},{"key":"10.1016\/j.coph.2019.01.001_bib0185","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02137889."},{"key":"10.1016\/j.coph.2019.01.001_bib0190","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01930175?term=VAY736&rank=8)."},{"key":"10.1016\/j.coph.2019.01.001_sbref0195","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2017.26","article-title":"Pemphigus","volume":"3","author":"Kasperkiewicz","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.coph.2019.01.001_bib0200","first-page":"16","article-title":"Investigation of serum APRIL and BAFF levels in pemphigus vulgaris patients in Southern Iran","volume":"14","author":"Torkamani","year":"2011","journal-title":"Iran J Dermatol"},{"key":"10.1016\/j.coph.2019.01.001_sbref0205","first-page":"108","article-title":"An open-label phase I clinical study to assess the safety of PI-0824 in patients with pemphigus vulgaris","volume":"125","author":"Anhalt","year":"2005","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.coph.2019.01.001_bib0210","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/S0140-6736(97)09278-7","article-title":"Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group","volume":"350","author":"Nashan","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.coph.2019.01.001_bib0215","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/sj.bmt.1703654","article-title":"Combination treatment of bullous pemphigoid with anti-CD20 and anti-CD25 antibodies in a patient with chronic graft-versus-host disease","volume":"30","author":"Szabolcs","year":"2002","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.coph.2019.01.001_bib0220","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1080\/00015550410022221","article-title":"Daclizumab: a novel therapeutic option in severe bullous pemphigoid","volume":"85","author":"Mockenhaupt","year":"2005","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.coph.2019.01.001_bib0225","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1111\/j.1365-2133.2004.05977.x","article-title":"A novel therapeutic option in pemphigus vulgaris: humanized monoclonal anti-CD25 antibody","volume":"150","author":"Renkl","year":"2004","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.coph.2019.01.001_sbref0230","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.intimp.2017.10.027","article-title":"Current and future treatment options for pemphigus: is it time to move towards more effective treatments?","volume":"53","author":"Tavakolpour","year":"2017","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.coph.2019.01.001_bib0235","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.2353\/ajpath.2008.080391","article-title":"Autoantibodies in the autoimmune disease pemphigus foliaceus induce blistering via p38 mitogen-activated protein kinase-dependent signaling in the skin","volume":"173","author":"Berkowitz","year":"2008","journal-title":"Am J Pathol"},{"key":"10.1016\/j.coph.2019.01.001_bib0240","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jdermsci.2016.12.010","article-title":"Nonpathogenic pemphigus foliaceus (PF) IgG acts synergistically with a directly pathogenic PF IgG to increase blistering by p38MAPK-dependent desmoglein 1 clustering","volume":"85","author":"Yoshida","year":"2017","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.coph.2019.01.001_bib0245","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1074\/jbc.M110.172874","article-title":"p38 MAPK activation is downstream of the loss of intercellular adhesion in pemphigus vulgaris","volume":"286","author":"Mao","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1016\/j.coph.2019.01.001_bib0250","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/ijd.13461","article-title":"Application of autologous hematopoietic stem cell transplantation for pemphigus","volume":"56","author":"Wang","year":"2017","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.coph.2019.01.001_bib0255","doi-asserted-by":"crossref","first-page":"9","DOI":"10.4103\/0019-5154.92667","article-title":"Allogenic hematopoietic stem cell transplantation in pemphigus vulgaris: a single center experience","volume":"57","author":"Vanikar","year":"2012","journal-title":"Indian J Dermatol"},{"key":"10.1016\/j.coph.2019.01.001_bib0260","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/dth.12327","article-title":"Dupilumab: a revolutionary emerging drug in atopic dermatitis and its possible role in pemphigus","volume":"29","author":"Tavakolpour","year":"2016","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.coph.2019.01.001_sbref0265","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.cyto.2015.09.017","article-title":"Interleukin 4 inhibition as a potential therapeutic in pemphigus","volume":"77","author":"Tavakolpour","year":"2016","journal-title":"Cytokine"},{"key":"10.1016\/j.coph.2019.01.001_sbref0270","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1007\/s12026-013-8411-1","article-title":"Refractory pemphigus foliaceus and Behcet\u2019s disease successfully treated with tocilizumab","volume":"56","author":"Caso","year":"2013","journal-title":"Immunol Res"},{"key":"10.1016\/j.coph.2019.01.001_bib0275","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.autrev.2009.01.012","article-title":"Interleukin-6 as a key player in systemic inflammation and joint destruction","volume":"8","author":"Fonseca","year":"2009","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.coph.2019.01.001_bib0280","first-page":"383","article-title":"Cytokines in the sera of patients with pemphigus vulgaris: interleukin-6 and tumour necrosis factor-alpha levels are significantly increased as compared to healthy subjects and correlate with disease activity","volume":"8","author":"D\u2019Auria","year":"1997","journal-title":"Eur Cytokine Netw"},{"key":"10.1016\/j.coph.2019.01.001_bib0285","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1046\/j.1365-4362.2001.01083.x","article-title":"TNFa and IL-6 are mediators in the blistering process of pemphigus","volume":"40","author":"Lo\u00b4pez-Robles","year":"2001","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.coph.2019.01.001_bib0290","doi-asserted-by":"crossref","first-page":"176","DOI":"10.3389\/fimmu.2015.00176","article-title":"Fully human monoclonal antibody inhibitors of the neonatal fc receptor reduce circulating IgG in non-human primates","volume":"6","author":"Nixon","year":"2015","journal-title":"Front Immunol"},{"key":"10.1016\/j.coph.2019.01.001_bib0295","unstructured":"https:\/\/www.syntimmune.com\/syntimmune-announces-positive-preliminary-results-from-clinical-proof-of-concept-trial-of-synt001-in-pemphigus-vulgaris-and-foliaceus\/. This multi-centre, open-label Phase 1b proof-of-concept trial of SYNT001 study showed positive preliminary results in pemphigus vulgaris and foliaceus patients."},{"key":"10.1016\/j.coph.2019.01.001_bib0300","unstructured":"https:\/\/www.raredr.com\/news\/orphan-drug-designation-granted-pemphigus-treatment-synt001."}],"container-title":["Current Opinion in Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489218300985?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489218300985?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T06:51:00Z","timestamp":1761461460000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471489218300985"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":60,"alternative-id":["S1471489218300985"],"URL":"https:\/\/doi.org\/10.1016\/j.coph.2019.01.001","relation":{},"ISSN":["1471-4892"],"issn-type":[{"value":"1471-4892","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacological advances in pemphigus","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coph.2019.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}